CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript
CareDx, Inc beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.24.
Source: insidermonkey.com
📰 Sure Lung News
Sure Lung News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sure Lung. Real-time updates on events, politics, business and more.
CareDx Shares Rise 10% After AlloSure Lung Testing Service Receives Medicare Coverage
By Chris Wack CareDx shares were up 10% at $10.69 after the company said its AlloSure Lung donor-derived cell-free DNA molecular testing service has received...
Chris Wack Allosure Lung Medicare Local Coverage Determination Molecular Testing Solid Organ Allograft Rejection Sure Lung
Source: marketwatch.com
CareDx's AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
AlloSure Lung Represents First dd-cfDNA Approved by Medicare for Lung Transplant Patients
United States Caredx Allosure Nirmal Sharma Appl Lab Lung Transplantation Program At Brigham Transplantation Network
Source: marketscreener.com
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management Experts Review Advancements in... | June 1, 2023
Source: marketscreener.com
AlloSure, the First dd-cfDNA in Heart and Kidney
AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients...
Source: globenewswire.com